Triple-negative breast cancer [TNBC, ER(−), PR(−), HER2(−)], which accounts for about 15% of breast cancers worldwide, is characterized by aggressive tumor behavior and a strong resistance to ant hormone treatment, chemotherapy, and targeted therapy [4–6]. This evidence concerns the gene ESR1 and breast cancer.